Department of Ophthalmology, Torbali State Hospital, Izmir, Turkey.
Department of Ophthalmology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Korean J Ophthalmol. 2020 Oct;34(5):398-403. doi: 10.3341/kjo.2020.0006. Epub 2020 Oct 5.
To evaluate the concentration of serum cystatin C (CysC) in patients with Graves' ophthalmopathy (GO) and the usability of the serum CysC concentrations in the follow-up of the disease.
Thirty patients with GO and 30 healthy age-matched volunteers were included in this cross-sectional study. GO was diagnosed based on the European Group on Graves' Orbitopathy consensus. Serum thyroid-stimulating hormone, free triiodothyronine, free thyroxine, and CysC concentrations were measured in the participants. The serum CysC concentrations were compared between patients with GO and controls. Patients with GO were subdivided into hyperthyroid and euthyroid patients, and their serum CysC concentrations were compared. In addition, the CysC concentrations in hyperthyroid and euthyroid patients with GO were compared separately with those of healthy subjects. Kruskal-Wallis test and Student's t-test were used for statistical evaluation.
The mean serum CysC concentrations in GO patients and controls were 1.04 ± 0.36 and 0.74 ± 0.09 mg/L, respectively. There was a statistically significant difference in the serum CysC concentrations between patients with GO and control subjects (p < 0.001). Fifteen patients had hyperthyroid status, and 15 patients had euthyroid status. The mean serum CysC concentrations in hyperthyroid and euthyroid patients with GO were 1.35 ± 0.22 and 0.72 ± 0.13 mg/L, respectively. Serum CysC concentrations were significantly higher in hyperthyroid patients than in euthyroid patients (p = 0.001). In addition, hyperthyroid patients had significantly higher serum CysC concentrations than healthy subjects. Among patients with GO, 21 and nine had mild and moderate-to-severe GO, respectively. Active and inactive GO were observed in eight and 22 patients, respectively.
The serum CysC concentrations in hyperthyroid patients were higher than those in healthy subjects. Moreover, hyperthyroid patients had higher serum CysC concentrations than euthyroid patients. Further studies with a larger sample size are needed to confirm these results.
评估 Graves 眼病（GO）患者血清胱抑素 C（CysC）的浓度，并探讨其在疾病随访中的可用性。
本横断面研究纳入了 30 名 GO 患者和 30 名年龄匹配的健康志愿者。GO 的诊断基于欧洲 Graves 眼病共识。检测参与者的血清促甲状腺激素、游离三碘甲状腺原氨酸、游离甲状腺素和 CysC 浓度。比较 GO 患者和对照组的血清 CysC 浓度。GO 患者分为甲状腺功能亢进和甲状腺功能正常两组，并比较其血清 CysC 浓度。此外，还分别比较了 GO 甲状腺功能亢进和甲状腺功能正常患者的 CysC 浓度与健康受试者的 CysC 浓度。采用 Kruskal-Wallis 检验和 Student's t 检验进行统计学评估。
GO 患者和对照组的平均血清 CysC 浓度分别为 1.04±0.36 和 0.74±0.09mg/L，两组间差异有统计学意义（p<0.001）。15 例患者为甲状腺功能亢进，15 例患者为甲状腺功能正常。GO 甲状腺功能亢进和甲状腺功能正常患者的平均血清 CysC 浓度分别为 1.35±0.22 和 0.72±0.13mg/L，甲状腺功能亢进患者的血清 CysC 浓度明显高于甲状腺功能正常患者（p=0.001）。此外，甲状腺功能亢进患者的血清 CysC 浓度明显高于健康受试者。GO 患者中，21 例为轻度，9 例为中重度。8 例为活动期，22 例为静止期。
甲状腺功能亢进患者的血清 CysC 浓度高于健康受试者，且甲状腺功能亢进患者的血清 CysC 浓度高于甲状腺功能正常患者。需要进一步开展更大样本量的研究来证实这些结果。
